Shotlee LogoShotlee
Blog
Download on theApp Store
Get it onGoogle Play
Skip to main content
Ozempic Era Over? BMJ Study on GLP-1 Weight Regain - Featured image
GLP-1 Medications

Ozempic Era Over? BMJ Study on GLP-1 Weight Regain

Shotlee Editorial Team
Written by Shotlee Editorial TeamHealth Research & Writing
·January 19, 2026·3 min read

On this page

  • Weight Regain: The Temporary Effect of GLP-1 Drugs
  • Treating Symptoms, Not Obesity's Root Causes
  • From Individual to Systemic Solutions
  • How Convenience Fuels the Obesity Epidemic
  • Ultra-Processed Foods and Addictive Design

Track Smart

Calculate active GLP-1 levels automatically with Shotlee.

Download →

The Ozempic hype may fade as a BMJ study shows users regain lost weight within 1.5 years after stopping GLP-1 drugs. These medications reduce appetite but require lifelong use and lifestyle changes for lasting results. Obesity stems from systemic issues like convenience culture and ultra-processed foods, not just willpower.

Share

On this page

  • Weight Regain: The Temporary Effect of GLP-1 Drugs
  • Treating Symptoms, Not Obesity's Root Causes
  • From Individual to Systemic Solutions
  • How Convenience Fuels the Obesity Epidemic
  • Ultra-Processed Foods and Addictive Design

In the three years since Ozempic captured public attention, the brand has become shorthand for all GLP-1 receptor agonists like Wegovy and Mounjaro. Once hailed as a wonder drug transforming waistlines and markets—from falling Krispy Kreme stocks to airline fuel savings—these treatments mimic a hormone that curbs appetite and controls blood sugar. Users often describe silencing "food noise," eliminating the willpower struggle in dieting.

Weight Regain: The Temporary Effect of GLP-1 Drugs

Recent data from the British Medical Journal published January 7 indicates users lose about 20% of body weight on these drugs. However, stopping treatment leads to full regain within 1.5 years. Ozempic delivers nation-altering benefits only with lifelong use.

  • Lifelong commitment raises costs—estimated at £10bn yearly for all eligible UK patients, half the drugs budget.
  • NICE guidelines limit some GLP-1s for weight loss to two years maximum.
  • Sustainable results demand lifestyle changes like "eat less, move more," mirroring past failed initiatives.

In essence, GLP-1 drugs resemble traditional diets: effective for loss but challenging for maintenance, as any yo-yo dieter knows.

Treating Symptoms, Not Obesity's Root Causes

Obesity demands addressing underlying drivers, not just symptoms. Factors include poverty, advertising, fast food, smartphone addiction, and sedentary lifestyles—not individual willpower alone.

UK stats highlight the crisis: 27% of men and 29% of women are obese today, up from 6% and 9% in 1980. Humanity thrived for 300,000 years with minimal obesity until industrialization eroded daily movement.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Get it onGoogle Play

How Convenience Fuels the Obesity Epidemic

  • Mechanized jobs and conveniences like cars, escalators, and vacuums reduced incidental activity.
  • Instant access via screens to food, banking, and shopping—from the sofa—increases eating while sedentary.
  • Shorter work hours yield more leisure, yet we feel too time-poor for exercise or home cooking.

The pandemic blurred work-play boundaries, amplifying always-on culture.

Ultra-Processed Foods and Addictive Design

Food has shifted to manufactured ultra-processed items, now over half of UK caloric intake. These hit the "bliss point"—optimal fat-salt-sugar ratios for maximum brain pleasure, overriding satiety signals.

Psychophysicist Howard Moskowitz defined this engineering. Historian David Courtwright terms it "limbic capitalism," where Big Food profits from addiction reward pathways, akin to social media or gambling. Early trials suggest GLP-1s may curb such addictions, but relying on Big Pharma for Big Food and Tech fixes feels dystopian.

From Individual to Systemic Solutions

689 UK anti-obesity initiatives since 1992 failed because obesity is collective, needing societal responses. Yet personal rebellion counts: cooking dinner or walking to takeaways defies profiteering from poor health.

For those on lifelong GLP-1s, apps like Shotlee help track doses consistently. Still, true change integrates drugs with environmental shifts for enduring weight management.

Source Information

Originally published by New Statesman.Read the original article →

Read next

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

What's the Deal with Peptides? The Hyped Market Under FDA Review
Health & Wellness

What's the Deal with Peptides? The Hyped Market Under FDA Review

An in-depth look at the FDA's review of unregulated peptide therapy, the safety concerns raised by experts, and the conflict between industry demand and clinical evidence.

8 min read
Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program
Health & Wellness

Eli Lilly, Novo Nordisk Address Awareness Gap for Medicare’s $50 GLP-1 Program

Learn how the new Medicare GLP-1 Bridge program works, which drugs are covered, and why major pharmaceutical companies are leading the awareness push for the $50 copay initiative.

8 min read
Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials
Medical Research

Eli Lilly's Retatrutide Shows Cardiovascular and Diabetic Benefits in Trials

Eli Lilly's investigational drug, retatrutide, has shown promising results in clinical trials, offering substantial weight loss and significant improvements in cardiovascular health and type 2 diabetes management.

7 min read

Same topic: Ozempic

All Ozempic articles →
Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics
Pharmaceutical Industry News

Samsung Biologics Acquires PolyPeptide for $1.8 Billion to Expand Peptide Therapeutics

Samsung Biologics has announced a major acquisition of PolyPeptide Group AG for $1.8 billion, marking a strategic expansion into the rapidly growing peptide therapeutics market, particularly for GLP-1 drugs.

8 min read

More in GLP-1 Medications

Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates
GLP-1 Medications

Ozempic's Rise: GLP-1 Drugs Curbing US Obesity Rates

CDC 2024 data shows US obesity rates dipping for the first time in decades, thanks to Ozempic and GLP-1 drugs. Originally a diabetes treatment, these medications mimic GLP-1 hormones for dramatic weight loss. Learn the serendipitous science behind them and their broader implications.

2 min read
Celebs Showing 'Ozempic Face' from GLP-1 Weight Loss Drugs
GLP-1 Medications

Celebs Showing 'Ozempic Face' from GLP-1 Weight Loss Drugs

Stars using GLP-1 medications like Ozempic for dramatic weight loss are sparking talk of 'Ozempic face': sunken cheeks, new wrinkles, and sagging skin. Cleveland Clinic endocrinologist Vinni Makin notes this gaunt look stems from rapid fat loss. Public figures face scrutiny as the trend grows.

1 min read
GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs
GLP-1 Medications

GLP-1 Drugs Save Airlines $580M Yearly in Fuel Costs

Popular GLP-1 drugs are delivering unexpected savings to airlines, with $580 million in annual fuel cost reductions projected for major U.S. carriers. Analyst Sheila Kahyaoglu's research links passenger weight loss to lower operating expenses. Discover how this weight management trend reshapes aviation economics.

2 min read
Share this article
  1. Home
  2. Blog
  3. Ozempic Era Over? BMJ Study on GLP-1 Weight Regain
Shotlee Editorial Team — Health Research & Writing
Written by

Shotlee Editorial Team

Health Research & Writing

Shotlee’s guides and articles are researched and written in-house by the Shotlee Editorial Team. We build every page from primary sources — FDA labels, official prescribing information, and peer-reviewed clinical trials — and cite them directly. Our content is educational and is not a substitute for advice from your own healthcare provider.

View all articles by Shotlee Editorial Team
Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Medication Trackers
  • Health Guides
  • Calculators
  • Compare Medications
  • Pricing

Resources

  • Health Blog
  • Support Center

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with for the community♥ for the community